title: [An attempt to use ofloxacin in patients with mucoviscidosis].
abstract: The literature data and the data of the authors on the pathogenesis and pathogenetic and etiotropic therapy of mucoviscidosis are presented. The use of ofloxacin as an antibacterial agent in the complex treatment of mucoviscidosis is considered expedient. The drug was administered intravenously in a dose of 400 mg twice a day for 5 days followed by the oral use of the drug in the form of tablets according to the same scheme. The microbiological investigation of the sputum specimens revealed diagnostically significant titers of Pseudomonas aeruginosa, Staphylococcus aureus and Klebsiella spp. The isolates except for one case (Ps.aeruginosa) were susceptible to ofloxacin. The treatment with ofloxacin in accordance with the above scheme resulted in a rapid improvement of the patient state: the intoxication lowered, the expectoration and the sputum viscosity decreased, the body temperature normalized by the 5th day. The drug tolerance after the intravenous and enteral administration was good. The intravenous injections of ofloxacin induced a 1.5-fold increase in the intensity of the neutrophil oxygen burst. After the drug enteral administration there was observed a 2-fold increase the intensity of the neutrophil oxygen burst.
authors.forename: A G
authors.initials: AG
authors.lastname: Chuchalin
authors.forename: A S
authors.initials: AS
authors.lastname: Sokolov
authors.forename: I D
authors.initials: ID
authors.lastname: Apul'tsina
authors.forename: E N
authors.initials: EN
authors.lastname: GUgutsidze
authors.forename: N V
authors.initials: NV
authors.lastname: Kuchkina
authors.forename: M V
authors.initials: MV
authors.lastname: Samsonova
mesh_terms: D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009504:Neutrophils / Q000187:drug effects; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D016897:Respiratory Burst; D013183:Sputum / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects
chemical_list: D000890:Anti-Infective Agents; D015242:Ofloxacin